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Abstract 
Objective: Vagal nerve activity – indexed by heart rate variability (HRV) – has been linked to altered pain 
processing and inflammation, both of which may underpin headache disorders and lead to cardiovascular disease 
(CVD). Here we examined the evidence for differences in parasympathetic (vagal) activity indexed by time- and 
frequency-domain measures of HRV in patients with headache disorders compared to healthy controls (HCs).  
Methods: A systematic review and meta-analysis was conducted on studies investigating group differences on 
resting-state, vagally-mediated HRV (vmHRV) including time- (root-mean-square of successive R-R-interval 
differences (RMSSD)) and frequency- (high-frequency HRV) domain measures. Studies eligible for inclusion were 
identified by a systematic search of the literature, based on the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement.  
Results: 7 studies reporting a total of 10 comparisons of patients with headache disorders (HF-HRV n=67, 
RMSSD n=122) and HCs (HF-HRV n=64, RMSSD n=125) were eligible for inclusion. Random-effects meta-
analysis revealed a significant main effect on RMSSD (Z = 2.03, p = 0.04; Hedges’ g = -0.63; 95% CI [-1.24, -
0.02]; k = 6) and similar pooled effect size estimates for HF-HRV when breathing was controlled (g = -0.30; 95% 
CI [-0.69; 0.10]) but not when breathing was not controlled (g = 0.02; 95% CI [-0.69; 0.74]). Controlling for 
breathing had no effect on RMSSD. 
Conclusion: vmHRV is reduced in patients with headache disorders, findings associated with a medium effect 
size. Suggestions for future research in this area are provided, emphasizing a need to investigate the impact of 
headache disorders and commonly comorbid conditions – including mental disorders – as well as the investigation 
of the risk for CVD in migraine in particular. We further emphasize the need for large scaled studies to investigate 
HRV as a mechanism mediating the association of migraine and CVD.  
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Autonomic nervous system (ANS) dysfunction has been linked to common headache disorders including migraine 
(1,2,3) and tension type headache (TTH, 4,5). The association between ANS dysfunction and migraine, in 
particular, is well documented within the literature. Heart rate variability (HRV) is the beat-to-beat variation in the 
heart rate and is a surrogate measure of parasympathetic (vagal) activity. Parasympathetic modulation of the heart 
rate is fast (timescale in the order of milliseconds) while sympathetic effects are much slower (6,7). Therefore, 
high-frequency (HF) HRV and time-domain measures reflecting these fast changes (i.e., the root-mean-square of 
successive R-R-interval differences, RMSSD) provide a readily available, surrogate measure of vagal-activity. 
Here we conducted a systematic review and meta-analysis to provide an objective and up-to-date assessment of 
this literature, and to clarify the association between headache and vagal function, as assessed by HRV. While 
most studies have emphasized a role for sympathetic hyperactivity in headache disorders, examining a potential 
role for vagal parasympathetic-activity may provide additional insights into the mechanism underlying headache 
disorders.  
Importantly, there is evidence that migraine with aura (MwA) is associated with increased risk of major 
CVD, myocardial infarction, ischemic stroke, and death due to ischemic CVD (8). Other studies found, that both 
MwA and migraine without aura (MwoA) are associated with CVD and risk factors for CVD (9,10). A recent 
systematic review found that migraine is associated with a twofold-increased risk of ischaemic stroke, which is 
only apparent among people who have MwA (11). Therefore, understanding the role of HRV in headache disorders 
might promote a deeper understanding of the increased risk for CVD in headache patients. 
Vagal impairment – as indexed by HRV – may further lead to heightened inflammatory processes, which 
have also been associated with migraine (12). In particular, impaired vagal efferent activity may lead to excessive 
inflammation via failure to inhibit release of pro-inflammatory cytokines, reflecting a poorly functioning anti-
inflammatory reflex (13-18). These inflammatory processes may cause prolonged, ongoing excitation of primary 
nociceptive neurons leading to chronic painful conditions. Recently, we were able to show that vagally-mediated 
HRV (vmHRV) predicts increased levels of inflammation four years later (19), providing evidence for the anti-
		
inflammatory reflex in humans. Vagal-nociceptive networks are also involved in pain processing (20), and 
decreased vagal-activity leads to greater somatic and visceral input via the spinothalamic track. Such loss of 
sensory integration due to decreased vagal activity may result in greater affective processing of nociceptive 
information that results in overstraining adaptive capabilities (21).  
Lower vmHRV is reported in a variety of chronic painful conditions, such as chronic neck pain (22), 
chronic pelvic pain (23), complex regional pain (24), fibromyalgia (25,26) and the irritable bowel syndrome (27). 
In light of this work, the vagus nerve is widely perceived as a promising target for therapeutic interventions in the 
treatment of chronic pain. An important area involved in descending inhibitory modulation of pain is the 
periaqueductal grey (PAG). It has been shown that stimulation of the ventral PAG increases HRV and decreases 
pain in humans with chronic pain (28). Given that this pathway is distinct from dorsal PAG stimulation, it has been 
suggested that analgesia with deep brain stimulation in chronic pain is associated with increased vagal 
parasympathetic activity (28). Considering these anatomical connections, the prominent role of the vagus nerve in 
pain processing, and promising findings on vagus nerve stimulation in subjects with chronic pain (29,30) – 
including migraine (31) and cluster headaches (32) – is slowly gaining recognition. Resting vagal-activity in 
headache patients might be more than a simple marker of ANS dysfunction; it may actually be a major contributor 
to the condition itself. Recently, we were able to show (21), a negative correlation of vmHRV and pain in 
multivariate adjusted analysis. Most interestingly – and deserving special notice – while individuals with chronic 
pain reported lower vagal activity, the correlation of pain severity and vmHRV was only present in respondents 
without chronic pain, suggesting that the descending inhibitory pathway via the vagus nerve is disturbed in persons 
with chronic pain (21). 
Chronic reductions in HRV are also associated with a variety of comorbidities that are, themselves 
associated with headache disorders. While decreased HRV increases risk for morbidity, especially CVD, and is an 
independent risk factor for mortality (33,34), headache disorders are also associated with comorbid conditions such 
as depression and anxiety (35,36), which are also associated with reductions in HRV (37,38). The lifetime 
prevalence of major depression is approximately three times higher in patients with migraine and in persons with 
severe headache disorders (39). Depression without CVD is associated with reduced HRV (37,40). While the 
		
underlying mechanisms in the association of migraine and psychiatric comorbidity remain unclear (41), vmHRV 
may provide a valuable tool to further investigate the association of migraine, CVD, and comorbid depression. The 
present systematic review and meta-analysis, reviews the current evidence on differences in resting-baseline 




2.1 Systematic Literature Search  
A systematic search of the literature, according to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement (42) was employed. PubMed, PsycNET/PsycINFO, CINAHL Plus, and Web of 
Science (WOS) databases were searched using the search terms “heart rate variability” and “headache” OR 
“migraine” (see Appendix A, for search strategy by database). The number of initial hits was recorded and 
additionally, a hand search (i.e., Google, Google Scholar and other sources) was performed. Reference lists of 
included studies were also checked for additional studies eligible for inclusion. After removing duplicates, 
abstracts of all articles were screened based on pre-defined inclusion criteria. Studies were included if they 
reported (i) an empirical investigation in (ii) humans and (iii) recorded HRV in (iv) headache patients compared to 
HCs. All titles meeting the inclusion criteria were retrieved and reviewed in full-text. Empirical investigations 
were defined as studies involving active data collection in human subjects. Reviews, meta-analysis, comments, or 
single-case reports were excluded. Animal studies and studies using a computational modeling approach (i.e., 
virtual data) were also excluded. The number of studies meeting the pre-specified inclusion criteria, number of 
studies excluded, and reasons for exclusion were recorded (Figure 1).  
 
2.2 Data Extraction 
Guidelines from the Task Force of the European Society of Cardiology and the North American Society of Pacing 
and Electrophysiology (43) were used to define the HRV measurements included for analysis. Only components 
reflecting primarily vagal cardiac modulation were included. These included the root-mean-square of successive R-
R-interval differences (RMSSD) or any spectral measure in the high frequency (HF) range of 0.15 – 0.4Hz (natural 
		
log transformed (lnHF), normalized (HFnu) or expressed as absolute power in ms2 (HFP)). Authors who reported 
HRV but who did not report RMSSD or HF-HRV, or did not provide sufficient quantitative data (e.g., only a 
graphical display), were contacted to request the necessary information to derive effect size estimates and 
confidence limits on the selected indices of HRV. Studies that reported multiple groups of headache patients were 
included as long as they reported findings against HCs, while studies that compared different groups of headache 
patients only were excluded. When multiple groups of headache patients (e.g., MwoA and MwA) were reported, 
each group was compared to the same group of HCs.  
 
2.3 Meta-Analysis  
Descriptive statistics (means and standard deviations (SD)) of time- (RMSSD) and frequency- (HF-HRV) domain 
measures of vagally-mediated HRV (vmHRV) from HRV recordings were extracted for each group. In case 
descriptive statistics were reported other than as mean and SD, data was imputed if possible (44,45). Where 
longitudinal or pre-post data were reported, only baseline resting HRV was included to minimize confounding 
effects by experimental manipulation and conflation of effect size estimates. True effect estimates were computed 
as adjusted standardized mean differences (Hedge’s g). We undertook meta-analyses using both fixed-effect and 
random-effects models. When results of both analyses are consistent (with confidence intervals (CI) of fixed-effect 
analyses being included within that of the random-effects analysis), the results from random-effects models are 
reported, as it better conveys the variability of data. However, when fixed-effect and random-effect models give 
different results, results of fixed effects analyses are reported, as they provide a more reliable estimate of the true 
effect (46). Possible sources of heterogeneity or inconsistency among trials in the magnitude or direction of effects 
were investigated. Heterogeneity was assessed using the standard I2 index, Chi-Square, and Tau2 tests (47). Bias 
was examined using a funnel plot of effect size against standard error for asymmetry. Meta-analytic computations 
were performed using RevMan (Version 5.3.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014). Risk of bias was also assessed in regards to reporting of comorbid conditions, medication 
intake at the time of testing, other restrictions prior to the recording of HRV (i.e., smoking, alcohol), and sample 
homogeneity including age, gender, headache diagnosis, headache history and frequency reported. Furthermore, 
		
meta-regression on potential covariates was conducted if sufficient data was available. These covariates include 
headache diagnosis, headache history (duration of disorder), symptom/attack frequency, age differences, gender 




3.1 Selection of Studies 
The systematic search of the literature revealed a total of 77 abstracts (after removing duplicates) that were 
screened for eligibility of inclusion within the present meta-analysis. A total of 18 studies were considered eligible 
for inclusion and retrieved in full-text (if possible). Of the 77 abstracts evaluated, 7 studies (48-54) yielding a total 
of 10 comparisons (HF-HRV k = 4, n = 67 headache patients and n = 64 healthy controls; RMSSD: k = 6, n = 122 
headache patients and n = 125 healthy controls) were included in the meta-analysis. The systematic literature 
search and reasons for exclusion of studies are illustrated in Figure 1.  
 
< Insert Figure 1 > 
 
 
3.2 Included Studies by Clinical Etiology 
Sample characteristics of included studies are summarized in Table 1. The majority of studies investigated patients 
with migraine. Nilsen and colleagues (49) investigated differences in HRV and spontaneous baroreflex sensitivity 
in female migraine patients (n = 16) compared to HCs (n = 14). They recorded HRV for 24 hours and 10 min of 
paced breathing. To avoid effect size inflation by including multiple measures from the same participants, only 
HRV indices derived from the 24-hour measurement period was used. Long-term recordings were also obtained by 
Tabata and colleagues (51) who investigated differences in the circadian rhythm (48-hour recordings of HRV) in 
27 patients with migraine and 24 HCs. The authors only report values derived from the Midline Estimating 
Statistic of Rhythms (MESOR) variable, a measure derived from cosinor analysis of long term recordings. There 
were no significant differences between headache patients and HCs. We included mean and SD of RMSSD from 
		
MESOR analysis for meta-analysis. The study by Vollono et al. (52) reported HRV data in different sleep stages 
and wakefulness and found a significant reduction of RMSSD, HF total power, and NN50 in patients with 
migraine compared to HCs during waking rest. The authors compare headache patients to a larger sample of HCs 
and age and sex-matched HCs, of which the later comparison was used for meta-analysis. Sanya and colleagues 
(53) assessed the autonomic regulation of the heart and peripheral blood vessels in migraine patients (n = 30) and 
HCs (n = 30) during baroreflex stimulation by oscillatory neck suction. Analysis of 5 min baseline recording 
(paced breathing), revealed no significant difference on measures of HF-HRV between patients and HCs. Thomsen 
and colleagues (54) compared cardiovascular response in 50 participants (n = 27 MwoA and n = 23 MwA) and 
HCs (n = 30), undergoing a head-up tilt test, a cold-pressor test, and a Valsalva maneuver. Data reported from the 
normal breathing baseline recording (150 consecutive heart beats, outside a migraine attack) expressed as MSD 
index (mean successive difference of the numeric values of the R-R intervals) were extracted and subjected to 
meta-analysis. The authors reported no significant difference between headache patients and HCs within this 
condition.  
 
< Insert Table 1 > 
 
Gass and Glaros (48) investigated whether HRV measures taken at rest from patients with headache 
disorders (n = 21; TTH, migraine, and mixed) differed significantly from those without headaches (n = 19). They 
reported that headache subjects had less variability in all HRV time domain measures, increased sympathetic 
nervous system (SNS) activity and decreased parasympathetic nervous system (PNS) activity compared to HCs. 
However, significant differences between groups were only reported for pNN50 and NN50 indices of HRV – both 
measures of vmHRV. RMMSD and HF-HRV derived from 5-minute recordings of HRV were subjected to the 
meta-analysis. Furthermore, one study by Tubani and colleagues (50) investigated differences in 24-hour 
recordings of HRV in patients with cluster headache (n = 8) compared to HCs (n = 8). Results revealed significant 
differences on low-frequency HRV (LF-HRV) but not HF-HRV. Reported HF-HRV values for the entire length of 
		
the recording (24-hour) were subjected to meta-analysis. Details on extracted HRV values and conditions are 
provided in Table 2.  
 
< Insert Table 2 > 
 
3.3 Meta-Analysis Main Effect  
First, we aimed to identify an overall effect of headache disorder on HRV, followed by subsequent analysis that 
aimed to investigate differences between clinical etiologies (diagnosis). Random-effect meta-analysis, on RMSSD, 
revealed that headache patients (n = 122) displayed significantly lower HRV compared to HCs (n = 125) (Z = 2.03, 
p = 0.04) (g = -0.63; 95% CI [-1.24, -0.02]; k = 6) indicating lower vagal activity in headache patients. CIs of 
fixed-effect models (Z = 4.35, p < 0.00001; Hedges’ g = -0.58; 95% CI [-0.85, -0.32]; k = 6) were included in 
those of random-effect models, thus random-effects are illustrated in Figure 2 (negative effect estimates reflect 
lower RMSSD in headache patients).  
 
< Insert Figure 2 > 
 
Random-effect meta-analyses on HF-HRV revealed no significant difference (Z = 1.26, p = 0.21) between 
headache patients (n = 67) and HCs (n = 64) (Hedges’ g = -0.22; 95% CI [-0.57, 0.12]; k = 4). As the CI of the 
fixed-effect model (Z = 1.26, p = 0.21; Hedges’ g = -0.22; 95% CI [-0.57, 0.12]; k = 4) was included in that of the 
random-effects model, results of random-effects are illustrated (Figure 3; negative effect estimates reflect lower 
HF in headache patients).  
 
< Insert Figure 3 > 
 
Significant heterogeneity was observed for RMSSD (see test results in Figure 2) and visual examination of funnel 
plots for HF (Figure 4a) and RMSSD (Figure 4b) revealed considerable asymmetry for RMSSD, indicating 
		
publication bias. Substantial heterogeneity was assumed if I² was greater than 50%, indicating that 50% of the 
variability in the outcome cannot be explained by sampling variation.  
 
< Insert Figure 4 > 
 
As we assumed, that the significant effect on RMSSD might relate to the considerable asymmetry of included 
studies, in particular the unlikely large effect reported by Tabata et al. (51), and given that this effect estimate was 
derived from a different analytical approach (MESOR-analysis) we excluded the study in a secondary analysis 
(leave-one-out meta-analysis). When excluding the study (see outlier in Figure 4), the significant main effect on 
RMSSD remained in fixed-effect meta-analysis (Z = 2.33, p = 0.02; Hedges’ g = -0.34; 95% CI [-0.63, -0.05]; k = 
5) (CIs of fixed-effect not included in those of random-effect models). Thus, we conclude, that the main effect 




3.4 Risk of Bias and Meta-Regression 
Risk of bias assessment (Table 3), revealed large risk of bias regarding the reporting of comorbid conditions (i.e., 
depression, anxiety), medication intake, and other restrictions prior to the examination (i.e., smoking, alcohol) that 
have substantial effects on HRV. Furthermore, reported samples from studies showed large heterogeneity in age, 
gender, headache history and symptom frequency.  
 
< Insert Table 3 > 
 
We performed a series of meta-regressions and sub-group analysis to identify potential covariates of the 
observed main effect found. There were not enough studies to address differences between studies recording HRV 
during uncontrolled (free) breathing and paced breathing using meta-regression on HF but RMSSD (Table 2). In a 
		
sub-group analysis on HF, studies that controlled or recorded breathing showed a significant greater pooled effect 
estimate for HF (g = -0.30; 95% CI [-0.69; 0.10]), compared to studies using uncontrolled conditions (g = 0.02; 
95% CI [-0.69; 0.74]). Controlled breathing was not a significant covariate of RMSSD (b = 0.822, SE = 0.637; 
95% CI [-0.427; 0.637]; p = 0.197). Further sub-groups analysis on etiology, indicated lower RMSSD in migraine 
patients (g = -0.93; 95% CI [-1.69; -0.18]) compared to a sample of patients with a variety of headache disorders, 
including migraine and TTH (g = -0.48; 95% CI [-0.48; 0.15]). Furthermore, patients with cluster headache 
showed increased HF (g = -0.48; 95% CI [-0.65; 1.41]) and patients with migraine decreased HF (g = -0.18; 95% 
CI [-0.63; 0.27]). No other covariate yielded a significant influence on the effects reported. 
     
4. DISCUSSION 
 
 Research on differences in resting state vagal activity in headache patients may have important implications for 
better understanding the elevated risk for CVD in these individuals. The present meta-analysis is the first to 
summarize the current evidence on vagal activity as indexed by vmHRV in headache patients. Meta-analysis 
revealed a significant and sizeable main effect on RMSSD (Hedges’ g = -0.63) and similar effect-size estimates for 
HF-HRV when breathing was controlled (Hedges’ g = -0.30). The effect for both selected indices of vmHRV 
revealed similar findings, indicating decreased vagal activity in headache patients. 
 While our initial analysis indicated significant differences between headache patients and healthy controls 
on RMSSD only, sub-group analysis showed an effect of respiratory control on the reported effects for HF-HRV, 
but not RMSSD. Our findings demonstrate that studies controlling for respiration reported larger effect sizes, than 
those that did not control for respiration. Thus, the results for RMSSD and HF-HRV are consistent when 
respiration is controlled. The fact that respiration had a greater effect on HF-HRV than on RMSSD is not 
surprising. Our group (55) as well others have shown that RMSSD is less affected by respiration than other indices 
of HRV including spectrally derived HF HRV (56). HRV indices derived from frequency domain analysis provide 
information of different quality and detail compared to time domain analysis (57). While RMSSD and HF are 
highly correlated (58), it has been suggested that time domain parameters can be estimated with less bias and 
considerably smaller variability as compared with frequency domain parameters (59, p. 290).  
		
While we selected the two most prominent and frequently used parameters of vagally-mediated HRV 
(RMSSD and HF) for the present analysis, other indices reflecting vagal activity such as the NN50 or pNN50 
component are of interest. Three studies by Gass and Glaros (48), Tabata (51) and Volono et al. (52) reported these 
and found significantly lower NN50 and pNN50 in headache patients compared to healthy controls in line with our 
findings of lower vagal activity indexed by RMSSD and HF. 
Of the four studies reporting RMSSD, only two studies initially reported significant differences between 
headache patients and healthy controls (HCs) (49,52), while three found no significant differences on the selected 
indices of vagal activity (48,51,54). One study that reported significant differences found RMSSD to be greater in 
headache patients (49), and one found RMSSD to be lower in headache patients (52). Except for one study (52), 
none of the studies on HF-HRV initially reported significant differences between headache patients and HCs 
(48,50,53). This further highlights the utility of meta-analysis to provide a more objective assessment of the extant 
literature. 
Results from sub-group analysis on diagnosis of headache disorder revealed lower vagal-activity in 
migraineuers compared to mixed samples of patients with a variety of headache disorders, including migraine and 
TTH, and patients with cluster headache. These findings provide first evidence for a unique association of migraine 
and vagal activity, lending further support for our hypothesis that reduced vagal activity may provide a 
physiological pathway linking migraine and CVD. However, it is important to note that there is an insufficient data 
to determine robust differences in vagal activity comparing different diagnosis of primary headache disorders. 
Regarding a potential pathway linking HRV and CVD in headache patients, the distinction between different 
headache disorders is crucial, as different diagnosis are associated with different risk factors for CVD (60), and it is 
proposed that different mechanism underlie the elevated CVD risk in MwA in comparison to other headache types 
(61,62). In general, symptom history and frequency – both important diagnostic qualities – are inadequately 
reported in most of the included studies, and as a result we did not have sufficient data to perform meta-regression 
on symptom/attack frequency. In fact only two studies provided adequate reporting of headache frequency (49,52) 
and headache history (52,53).  We analyzed the reported mean duration of headache symptoms as a potential 
covariate on RMSSD but found no significant differences. Given that, in most cases, studies on migraine patients 
		
did not distinguish between migraine with and without aura symptoms, we were not able to address the potential 
impact of migraine aura. Critically, past research demonstrates that the association of migraine and CVD might 
depend on the presence of aura symptoms (63). One of the included studies explicitly addressed differences in 
migraine patients with and without aura (54), but found no significant differences. Given that we were not able to 
address differences in vagal activity between MwoA and MwA using meta-analysis, future studies on differences 
between the two etiologies are encouraged. Thus, future studies are needed to (i) compare different diagnosis of 
primary headache disorders, (ii) investigate the association of symptom severity (i.e., frequency, intensity, duration 
of attacks) and vmHRV, as well as (iii) the (longitudinal) association of headache history and vmHRV, and (iv) 
address differences in migraine with and migraine without aura. 
 While we found age not to be a significant covariate of HF-HRV, interpretations should be drawn with 
caution given the relatively small mean differences on age between samples (Table 1) included in the present 
analysis. HRV decreases with age (64-67) and future studies should investigate age as important covariate – in 
particular linking the age of onset of symptoms and age at time of HRV recording. We were unable to explore 
potential gender differences in HRV that have recently been reported (68-72) as included studies only reported 
mixed (women and men) samples. Lastly, we compared short- (< 1 hour) with long-term recordings (24 or 48 
hours) using meta-regression, but found no significant differences. It is noted that guidelines for the measurement 
of HRV (45) suggest that spectral analysis of 24-hour long-term HRV (where spectral estimates are calculated over 
long data epochs that are not likely to be stationary) may not accurately reflect autonomic modulation, which may 
be better captured by estimates based on shorter data epochs. Future studies should take this into account. 
Furthermore, no study recording HRV for at least 24 hours (49-51) addressed potential differences between awake 
and sleep periods. The data by Vollono et al (52), shows, that such analyses may be important to address the 
involvement of the vagus nerve, as during nighttime, movement artifacts are minimized and the contribution of 
sympathetic influences is low, in particular when further exploring sleep-related headache. 
 The present systematic review and meta-analysis faces several limitations that need to be addressed in 
future research, especially, given the availability of primary research on this topic. Overall, this analysis was 
performed on a relatively small data set, including only 7 studies, all with high risk of bias (Table 3). We were not 
		
able to retrieve one full-text of a study conducted in Poland (73), which compared 40 headache patients to 62 HCs. 
One study conducted in children and adolescents (74) with potential data of interest, that also reviewed the existing 
literature without taking a meta-analytical approach, did not report the respective indices of interest (HF-HRV or 
RMSSD) and we were not able to obtain the data. Two studies published in 1993 by the same group of authors, 
investigating ANS function in patients with TTH (75) and migraine (76) did not report sufficient baseline data (i.e., 
only graphical display instead of reporting exact means and SDs) on vagal indices of HRV, and again, we were not 
able to obtain the data. Another three studies, two by Zigelmann et al. (77,78) and one by Appel et al. (79) were 
insufficient in terms of reporting data of interest, and we were unable to contact the authors. Pierangeli and 
colleagues (80) explored differences in cardiovascular responses to the tilt test and Valsalva maneuver in HCs 
compared to patients with MwoA and MwA, but only provide data on HF as graphical display and we were unable 
to contact the authors.. Within a commentary to a paper by Kurth et al. (10), Perciaccante et al. (81) report some 
preliminary findings on HRV differences in headache patients compared to HCs. However again, we were not able 
to obtain the necessary data to include the study in the present meta-analysis. The study by Shechter et al. (82) 
reported RR variation but no indices of vmHRV, and we were not able to obtain the data. We also requested details 
on the HRV measures taken in the study by Aygül et al. (83) that only reported RR variation but not values for HF 
and RMSSD, but did not receive a response from the authors. Studies that illustrate but insufficiently report 
findings on vagal indices of HRV are inconsistent, reporting lower parasympathetic activity in headache patients 
compared to healthy controls (73) or no differences (74-76,79). Given the exclusion of these 11 studies (73-83) 
with potential data of interest, the present analysis is limited and not completely reflective of the existing evidence. 
In addition, it is critical to note, that all included studies carry a potential high risk of bias (Table 3). In 
general, most studies failed to report medication in sufficient detail, an important issue considering well-known 
effects on HRV (37,84). Furthermore, most studies failed to control for frequent comorbid conditions described in 
the context of headache disorders (i.e. anxiety and depression) that are also linked with HRV. We also found large 
methodological differences between studies regarding the recording of HRV. Specifically, some studies asked 
participants to avoid exercise, smoking or alcohol consumption prior to the recording of HRV, while others did not 
		
control for such influences. We addressed publication bias and study-heterogeneity excluding one study on 
RMSSD (38), reporting an unlikely large effect and found the main-effect for RMSSD to hold.  
Lower vagal activity, indexed by vmHRV, is associated with an increased risk for CVD. Furthermore, 
lower vmHRV is associated with greater inflammation and less inhibitory control in pain processing. Chronic pain 
patients show lower HRV and vagus nerve stimulation in chronic pain patients (including migraine and cluster 
headache) may lead to pain release and a simultaneous increase in HRV. Therefore, reduced vmHRV may reflect 
an important mechanism underlying headache disorders and an increased risk for CVD in headache patients. Three 
potential models (61) may underpin the link between headache and CVD: (i) the frequent experience of headache, 
may lead to life-style changes such as decreased physical activity, altered smoking habits or an unhealthy diet – all 
of which may reduce vmHRV – that elevate CVD risk; (ii): an unfavorable CVD risk profile is associated with 
reduced vmHRV, which could subsequently lead to the development of headache; (iii) genetic or environmental 
causes common to both headache and an unfavorable CVD risk profile may lead to reductions in vmHRV. Here we 
emphasize how vmHRV may relate to headache disorders and CVD, however future research is needed to 
determine whether vmHRV is actually a mediating factor of headache disorders and its relationship to CVD. 
Future studies are needed to: (i) carefully distinguish between different diagnosis based on established criteria, (ii) 
examine homogenous samples of patients of the same age, gender, with the same diagnosis, and headache 
characteristics (i.e., frequency, intensity, headache history), that (iii) control for comorbid conditions and (iv) 





We demonstrate here that vmHRV is reduced in patients with primary headache disorders, findings associated with 
a large effect size. Future studies are needed to further examine the association between headache disorders - and 
migraine in particular – vmHRV, common comorbid conditions and risk for CVD. We emphasize the necessity of 






We thank Fiorella Pepe, Executive Secretary, Segreteria Società Italiana di Medicina Interna, for providing us with 
the full-text of one included paper. AHK and JFT would also like to acknowledge the financial support of 
FAPESP, a Brazilian research funding institution in the state of São Paulo, and that of Ohio State University, 
which has helped to initiate collaborative activities between the authors of the current manuscript.   
		
References 
* indicates that the study was included in the meta-analysis 
 
1. Peroutka SJ. Migraine: A chronic sympathetic nervous system disorder. Headache 2004; 44: 53-64. 
2. Rubin LS, Graham D, Pasker R, Calhoun W. Autonomic nervous system dysfunction in common migraine. 
Headache 1985; 25: 40-48. 
3. Thomsen LL, Olesen J. The autonomic nervous system and the regulation of arterial tone in migraine. Clin 
Auton Res 1995; 5: 243-250. 
4. Yerdelen D1, Acil T, Goksel B, Karataş M. Autonomic function in tension-type headache. Acta Neurol Belg 
2007; 107:108-111. 
5. Yerdelen D, Acil T, Goksel B, Karatas M. Heart rate recovery in migraine and tension-type headache. 
Headache 2008; 48: 221-225. 
6. Levy MN. Neural control of cardiac function. Baillieres Clin Neurol 1997; 6: 227–244. 
7. Appelhans, Bradley M.; Luecken, Linda J. Heart rate variability as an index of regulated emotional 
responding. Review of General Psychology 2006;, 10: 229-240. 
8. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular 
disease in women. JAMA 2006; 296: 283-291. 
9. Bigal ME, T. Kurth, N. Santanello, et al. Migraine and cardiovascular disease: A population-based study. 
Neurology 2010; 74: 628-635 
10. Kurth T, Gaziano JM, Cook NR, Bubes V, Logroscino G, Diener HC, MD, Buring JE. Migraine and Risk of 
Cardiovascular Disease in Men. Arch Intern Med 2007; 167: 795-801.  
11. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: 
systematic review and meta-analysis. BMJ 2009; 339: b3914 
12. Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology 2005; 64: S9-15. 
13. Thayer JF. Vagal tone and the inflammatory reflex. Cleve Clin J Med 2009; 76: S23–6. 
14. Thayer JF, Fischer JE. Heart rate variability, overnight urinary norepinephrine and C-reactive protein: 
evidence for the cholinergic anti-inflammatory pathway in healthy human adults. J Intern Med 2009; 265: 
439–447. 
15. von Känel R, Thayer JF, Fischer JE. Nighttime vagal cardiac control and plasma fibrinogen levels in a 
population of working men and women. Ann Noninvasive Electrocardiol 2009; 14: 176–184. 
16. Huston JM, Tracey KJ. The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory 
pathway and implications for therapy. J Intern Med 2011; 269: 45–53. 
17. Thayer JF, Loerbroks A, Sternberg EM. Inflammation and cardiorespiratory control: the role of the vagus 
nerve. Respir Physiol Neurobiol 2011; 178: 387–394.  
		
18. Papaioannou V, Pneumatikos I, Maglaveras N. Association of heart rate variability and inflammatory 
response in patients with cardiovascular diseases: current strengths and limitations. Front Physiol 2013; 4: 
174. 
19. Jarczok MN, Koenig J, Mauss D, Fischer JE, Thayer JF. Lower heart rate variability predicts increased level 
of C-reactive protein 4 years later in healthy, nonsmoking adults. J Intern Med 2014; online First. doi: 
10.1111/joim.12295 
20.  Randich A, Gebhart GF. Vagal afferent modulation of nociception. Brain Res Brain Res Rev. 1992 May-
Aug;17(2):77-99. 
21. Koenig J, Loerbroks A, Jarczok MN, Fischer JE, Thayer JF. Chronic Pain and Heart Rate Variability in a 
Cross-Sectional Occupational Sample: Evidence for Impaired Vagal Control. Clin J Pain; in press  
22.  Kang JH, Chen HS, Chen SC, Jaw FS. Disability in patients with chronic neck pain: heart rate variability 
analysis and cluster analysis. Clin J Pain 2012;28:797–803. 
23.  Cho DS, Choi JB, Kim YS, Joo KJ, Kim SH, Kim JC, Kim HW. Heart rate variability in assessment of 
autonomic dysfunction in patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 
2011;78:1369–1372. 
24.  Terkelsen AJ, Mølgaard H, Hansen J, Finnerup NB, Krøner K, Jensen TS. Heart rate variability in complex 
regional pain syndrome during rest and mental and orthostatic stress. Anesthesiology 2012;116:133–146. 
25.  Martínez-Lavín M, Hermosillo AG, Rosas M, Soto ME. Circadian studies of autonomic nervous balance in 
patients with fibromyalgia: A heart rate variability analysis. Arthritis & Rheumatism 1998;41:1966–1971. 
26.  Lerma C, Martinez A, Ruiz N, Vargas A, Infante O, Martinez-Lavin M. Nocturnal heart rate variability 
parameters as potential fibromyalgia biomarker: correlation with symptoms severity. Arthritis Res Ther 
2011;13:R185. 
27.  Mazurak N, Seredyuk N, Sauer H, Teufel M, Enck P. Heart rate variability in the irritable bowel syndrome: a 
review of the literature. Neurogastroenterol Motil 2012;24:206–216. 
28.  Pereira EA, Lu G, Wang S, Schweder PM, Hyam JA, Stein JF, Paterson DJ, Aziz TZ, Green AL. Ventral 
periaqueductal grey stimulation alters heart rate variability in humans with chronic pain. Exp Neurol 
2010;223:574–581. 
29.  Multon S, Schoenen J. Pain control by vagus nerve stimulation: from animal to man...and back. Acta Neurol 
Belg 2005;105:62-67. 
30.  George MS, Nahas Z, Bohning DE, Kozel FA, Anderson B, Chae JH, Lomarev M, Denslow S, Li X, Mu C. 
Vagus nerve stimulation therapy: a research update. Neurology 2002;59:S56-61 
31.  Hord ED, Evans MS, Mueed S, Adamolekun B, Naritoku DK. The effect of vagus nerve stimulation on 
migraines. J Pain 2003;4:530–534.  
		
32.  Mauskop A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. 
Cephalalgia. 2005;25(2):82-6. 
33. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and 
cardiovascular disease risk factors. Int J Cardiol 2010; 141: 122-131.  
34. Kemp AH, Quintana DS.. The relationship between mental and physical health: insights from the study of 
heart rate variability. Int J Psychophysiol 2013, 89: 288–296.  
35. Pesa J, Lage MJ. The medical costs of migraine and comorbid anxiety and depression. Headache 2004; 44: 
562-570. 
36. Antonaci F, Nappi G, Galli F, Manzoni GC, Calabresi P, Costa A. Migraine and psychiatric comorbidity: a 
review of clinical findings. J Headache Pain 2011; 12: 115-125.  
37. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM. Impact of Depression and 
Antidepressant Treatment on Heart Rate Variability: A Review and Meta-Analysis. Biological Psychiatry 
2010; 67: 1067–1074.  
38. Kemp AH, Brunoni AR, Santos IS, Nunes MA, Dantas EM, Carvalho de Figueiredo R, Pereira AC, Ribeiro 
AL, Mill JG, Andreão RV, Thayer JF, Benseñor IM, Lotufo PA. Effects of Depression, Anxiety, 
Comorbidity, and Antidepressants on Resting-State Heart Rate and Its Variability: An ELSA-Brasil Cohort 
Baseline Study. American Journal of Psychiatry 2014 [online first] 
39. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM. Headache and major depression: is 
the association specific to migraine? Neurology 2000; 54: 308-313. 
40. Kemp AH,    Quintana DS, Felmingham KL, Matthews S, Jelinek HF. Depression, Comorbid Anxiety 
Disorders, and Heart Rate Variability in Physically Healthy, Unmedicated Patients: Implications for 
Cardiovascular Risk. PLOS One 2012; DOI: 10.1371/journal.pone.0030777 
41. Antonaci F, Nappi G, Galli F, Manzoni GC, Calabresi P, Costa A. Migraine and psychiatric comorbidity: a 
review of clinical findings. J Headache Pain 2011;12:115-125.  
42. Moher D, Liberati A, Tetzlaff J, The PRISMA Group. Preferred reporting items for systematic reviews and 
meta-analyses: the PRISMA statement. BMJ 2009; 151: 264–269. 
43. Task force of the European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology. Heart rate variability: Standards of measurement, physiological interpretation, and 
clinical use. Eur Heart J 1996; 17: 354–381. 
44.  Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a 
lack of standardization in methods for handling missing variance data. J Clin Epidemiol. 2006; 59: 342–353. 
45.		 Glass GV, McGaw B, Smith ML. Measuring study findings. In: Glass GV, McGaw B, Smith ML, editors. 
Meta-analysis in social research. Beverly Hills, CA: Sage Publications; 1981. pp. 93–152. 
		
46.  Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Online 
available: http://handbook.cochrane.org 
47. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558. 
48. *Gass JJ, Glaros AG. Autonomic dysregulation in headache patients. Appl Psychophysiol Biofeedback 2013 
38: 257-263.  
49. *Nilsen KB, Tronvik E, Sand T, Gravdahl GB, Stovner LJ. Increased baroreflex sensitivity and heart rate 
variability in migraine patients. Acta Neurol Scand 2009; 120: 418-423.  
50. *Tubani L, Baratta L, Giorgino F, Delfino M, Fiore G, Golluscio V, Giacovazzo M. Heart rate variability in 
cluster headache. Ann Ital Med Int 2003; 18: 42-46. 
51. *Tabata M, Takeshima T, Burioka N, Nomura T, Ishizaki K, Mori N, Kowa H, Nakashima K. Cosinor 
analysis of heart rate variability in ambulatory migraineurs. Headache 2000; 40: 457-463. 
52. *Vollono C, Gnoni V, Testani E, Dittoni S, Losurdo A, Colicchio S, Di Blasi C, Mazza S, Farina B, Della 
Marca G. Heart rate variability in sleep-related migraine without aura. J Clin Sleep Med 2013; 9: 707-714. 
53. *Sanya EO, Brown CM, von Wilmowsky C, Neundörfer B, Hilz MJ. Impairment of parasympathetic 
baroreflex responses in migraine patients. Acta Neurol Scand 2005; 111: 102–107. 
54. *Thomsen LL, Iversen HK, Boesen F, Olesen J. Transcranial Doppler and cardiovascular responses during 
cardiovascular autonomic tests in migraineurs during and outside attacks. Brain 1995; 118: 1319–1327. 
55. Hill LK, Siebenbrock A. Are all measures created equal? Heart rate variability and respiration - biomed 2009. 
Biomed Sci Instrum. 2009;45:71-6. 
56. Penttilä J., Helminen A., Jartti T., Kuusela T., Huikuri H. V., Tulppo M. P., Coffeng R., Scheinin H. Time 
domain, geometrical and frequency domain analysis of cardiac vagal outflow: effects of various respiratory 
patterns. Clin. Physiol 2001; 21, 365–376 
57. Sinnreich R, Kark JD, Friedlander Y, Sapoznikov D, Luria MH. Five minute recordings of heart rate variability 
for population studies: repeatability and age-sex characteristics. Heart 1998;80(2):156-62. 
58. Goedhart AD, van der Sluis S, Houtveen JH, Willemsen G, de Geus EJ. Comparison of time and frequency 
domain measures of RSA in ambulatory recordings. Psychophysiology. 2007 Mar;44(2):203-15. 
59. Kuss O, Schumann B, Kluttig A, Greiser KH, Haerting J. Time domain parameters can be estimated with less 
statistical error than frequency domain parameters in the analysis of heart rate variability. J Electrocardiol 
2008;41(4):287-91 
60. Cirillo M, Stellato D, Lombardi C, De Santo NG, Covelli V. Headache and cardiovascular risk factors: 
positive association with hypertension. Headache 1999;39: 409-416. 
61. Winsvold BS, Hagen K, Aamodt AH, Stovner LJ, Holmen J, Zwart JA. Headache, migraine and 
cardiovascular risk factors: the HUNT study. Eur J Neurol 2011;18: 504-511.  
		
62. Bigal ME, Kurth T, Hu H, Santanello N, Lipton RB. Migraine and cardiovascular disease: possible 
mechanisms of interaction. Neurology 2009;72: 1864-1871.  
63. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular 
disease in women. JAMA. 2006 Jul 19;296(3):283-91. 
64. Zhang J. Effect of age and sex on heart rate variability in healthy subjects. J Manipulative Physiol Ther 
2007; 30: 374–279. 
65. Yeragani VK, Sobolewski E, Kay J, Jampala VC, Igel G. Effect of age on long-term heart rate variability. 
Cardiovasc Res 1997; 35: 35–42. 
66. Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate variability and 
heart rate: relations to age and gender over nine decades. J Am Coll Cardiol 1998; 31: 593–601. 
67. Reardon M, Malik M. Changes in heart rate variability with age. Pacing Clin Electrophysiol 1996; 19: 1863–
1866. 
68. Saleem S, Hussain MM, Majeed SM, Khan MA. Gender differences of heart rate variability in healthy 
volunteers. J Pak Med Assoc 2012; 62: 422–425. 
69. Ramaekers D, Ector H, Aubert AE, Rubens A, Van de Werf F. Heart rate variability and heart rate in healthy 
volunteers. Is the female autonomic nervous system cardioprotective? Eur Heart J 1998; 19: 1334–1341. 
70. Tanaka M, Kimura T, Goyagi T, Nishikawa T. Gender differences in baroreflex response and heart rate 
variability in anaesthetized humans. Br J Anaesth 2004; 92: 831–835. 
71. Huikuri HV, Pikkujämsä SM, Airaksinen KE, Ikäheimo MJ, Rantala AO, Kauma H, Lilja M, Kesäniemi 
YA. Sex-related differences in autonomic modulation of heart rate in middle-aged subjects. Circulation 
1996; 94: 122–125. 
72. Hu DD, Thayer JF. A meta-analysis of sex differences in heart rate variability. Psychosomatic Medicine 
2014; 76: A10-A11. 
73. Prusiński A, Trzos S, Rozentryt P, Durko A, Kozłowski JW, Kozubski W, Sokołowski P. [Studies of heart 
rhythm variability in migraine. Preliminary communication]. [Article in Polish] Neurol Neurochir Pol 1994; 
28: 23-27. 
74. Ebinger F, Kruse M, Just U, Rating D. Cardiorespiratory regulation in migraine. Results in children and 
adolescents and review of the literature. Cephalalgia 2006; 26: 295-309. 
75. Pogacnik T, Sĕga S, Mesec A, Kiauta T. Autonomic function testing in patients with tension-type headache. 
Headache 1993; 33: 63-68. 
76. Pogacnik T, Sega S, Pecnik B, Kiauta T. Autonomic function testing in patients with migraine. Headache 
1993; 33: 545-550. 
		
77. Zigelman M, Kuritzky A, Appel S, Davidovitch S, Zahavi I, Hering R, Akselrod S. Propranolol in the 
prophylaxis of migraine--evaluation by spectral analysis of beat-to-beat heart rate fluctuations. Headache 
1992; 32: 169-174. 
78. Zigelman M, Appel S, Davidovitch S, Kuritzky A, Zahavi I, Akselrod S. The effect of verapamil calcium 
antagonist on autonomic imbalance in migraine: evaluation by spectral analysis of beat-to-beat heart rate 
fluctuations. Headache 1994; 34: 569-577. 
79. Appel S, Kuritzky A, Zahavi I, Zigelman M, Akselrod S. Evidence for instability of the autonomic nervous 
system in patients with migraine headache. Headache 1992; 32: 10-17. 
80. Pierangeli G, Parchi P, Barletta G, Chiogna M, Lugaresi E, Cortelli P. Power spectral analysis of heart rate 
and diastolic blood pressure variability in migraine with and without aura. Cephalalgia 1997; 17: 756-760 
81. Perciaccante A, Fiorentini A, Valente R, Granata M, Tubani L. Migraine and heart rate variability. Arch 
Intern Med 2007; 167: 2264.  
82. Shechter A, Stewart WF, Silberstein SD, Lipton RB. Migraine and autonomic nervous system function: a 
population-based, case-control study. Neurology 2002; 58: 422-427. 
83. Aygül R, Deniz O, Orhan A, Koçak N, Kaya MD, Ulvi H. R-R interval variation in migraine patients. 
Eastern Journal of Medicine 2006 11: 1-6. 
84. Licht CMM, de Geus EJC, van Dyck, R, Penninx BWJH. Longitudinal evidence for unfavorable effects of 











Appendix A – Search Strategy by Database 
 
PubMed: (((headache) OR migraine)) AND heart rate variability: 63 hits; PsycNET/PsycINFO: (Any 
Field:(headache) OR Any Field:(migraine)) AND (Any Field:(heart rate variability)): 0 hits; CINAHL Plus: heart 
rate variability AND (migraine OR headache): 17 hits; WOS: (TITLE: heart rate variability) AND (TITLE: 
(migraine) OR TITLE: (headache)): 13 hits 
 
 
Figure Captions and Legends 
 
Figure 1. Systematic Literature Search Flow Chart; k: number of included comparisons on respective measure 
of vmHRV  
 
Figure 2. Random-Effect Meta-Analysis Main Effect Forrest Plot for RMSSD  
 
Figure 3. Random-Effect Meta-Analysis Main Effect Forrest Plot for HF-HRV 
 
Figure 4. Funnel Plot for (a) RMSSD and (b) HF-HRV; SMD: standardized mean difference; SE: standard 
error 
 
